I am very happy for Chris and whoever else has benefited from this treatment . Revimmune is so far an exciting option. But I don't think your "either go out tortured or go out mercifully" point of view is exactly valid.
Everyone and his brother are now in pursuit of this disease.
Just today, there was an announcement of an ms vaccine that could be available in 5 years
Wanna get the real scoop? Look what the money says. Here is a prediction of the MS Market.. it's pretty darn positive
Underserved Multiple Sclerosis Therapy Market Gets a Lifeline with the Development of Numerous Treatment Options
Healthcare companies across all tiers of competition are beginning to sit up and take notice of the U.S. multiple sclerosis (MS) market, following a spate of innovations in therapies. Big pharma, specialty pharma, niche pharma, biotechnology, and start-up companies could soon fill the vacuum created by the lack of an outstanding treatment option. "The pipeline for MS is robust, with a strong mix of early stage and late stage products, offering improved methods of treating and possibly, curing the disease," says the analyst of this research service.
The market is expected to experience a boom between 2007 and 2013 with the launch of oral therapies as well as improved versions of interferons. Innovations will stand market participants in good stead, since healthcare providers are hoping to improve the standard of care and patient compliance. Multiple sclerosis treatment could go through a paradigm change due to the introduction of these therapies, since patients who failed interferon therapy or quit treatment due to side effects will still have an array of options, unlike earlier.
Wide-ranging Therapies in the Pipeline Address Various Types of Multiple Sclerosis
"The pipeline for MS treatments includes a variety of innovative treatment options ranging from oral therapies to vaccine-based treatments," notes the analyst. "While traditional injection-based interferon therapies continue to remain the cornerstone of treatment, the next generation of therapies in development is dominated by oral formulations that cater predominantly to the relapsing remitting type of MS."
The unmet medical needs in primary progressive MS (PPMS) and secondary progressive MS (SPMS) segments are opening up significant market expansion opportunities for participants. Vendors are testing existing products for label expansion into other market segments, while simultaneously working on launching innovative therapies for the same purpose